Continuous Therapy Versus Fixed Duration of Therapy in Patients With Newly Diagnosed Multiple Myeloma.
暂无分享,去创建一个
M. Dimopoulos | M. Boccadoro | A. Nagler | R. Hájek | A. Larocca | F. Gay | T. Guglielmelli | G. Ciccone | M. Delforge | F. Di Raimondo | P. Musto | F. Cavallo | A. Palumbo | M. Petrucci | C. Nozzoli | F. Patriarca | P. Corradini | M. Cavo | C. Jacques | I. Hardan | F. Donato | G. Benevolo | Zhinuan Yu | T. Caravita | C. Cerrato | S. Pezzatti | Luana Boccadifuoco | D. Vincelli | Chiara Cerrato
[1] M. Boccadoro,et al. Autologous transplantation and maintenance therapy in multiple myeloma. , 2014, The New England journal of medicine.
[2] Christian Jacques,et al. Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. , 2014, The New England journal of medicine.
[3] M. Boccadoro,et al. Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] M. Dimopoulos,et al. PFS2 In Elderly Patients With Newly Diagnosed Multiple Myeloma (NDMM): Results From The MM-015 Study , 2013 .
[5] Renhao Li,et al. Specific Inhibition Of Ectodomain Shedding Of GPIba By Targeting Its Shedding Cleavage Site , 2013 .
[6] P. Moreau,et al. Lenalidomide Maintenance After Stem-Cell Transplantation For Multiple Myeloma: Follow-Up Analysis Of The IFM 2005-02 Trial , 2013 .
[7] M. Dimopoulos,et al. Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN). , 2013, Blood.
[8] Wanli Li,et al. Maintenance Therapy with Immunomodulatory Drugs after Autologous Stem Cell Transplantation in Patients with Multiple Myeloma: A Meta-Analysis of Randomized Controlled Trials , 2013, PloS one.
[9] S. Trudel,et al. A randomized phase 3 trial of thalidomide and prednisone as maintenance therapy after ASCT in patients with MM with a quality-of-life assessment: the National Cancer Institute of Canada Clinicals Trials Group Myeloma 10 Trial. , 2013, Blood.
[10] F. Cavallo,et al. Have drug combinations supplanted stem cell transplantation in myeloma? , 2012, Hematology. American Society of Hematology. Education Program.
[11] M. Kurokawa,et al. Thalidomide maintenance therapy for patients with multiple myeloma: meta-analysis. , 2012, Leukemia research.
[12] M. Beksac,et al. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. , 2012, The New England journal of medicine.
[13] B. Pégourié,et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. , 2012, The New England journal of medicine.
[14] K. Owzar,et al. Lenalidomide after stem-cell transplantation for multiple myeloma. , 2012, The New England journal of medicine.
[15] M. Beksac,et al. IMWG consensus on maintenance therapy in multiple myeloma. , 2012, Blood.
[16] G. Morgan,et al. Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results , 2012, Haematologica.
[17] G. Morgan,et al. The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis. , 2012, Blood.
[18] P. Fayers,et al. Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials. , 2011, Blood.
[19] M. Boccadoro,et al. Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] P. Fayers,et al. Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma. , 2010, Blood.
[21] P. Sonneveld,et al. Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] M. Deininger,et al. How much and how long: tyrosine kinase inhibitor therapy in chronic myeloid leukemia. , 2010, Clinical lymphoma, myeloma & leukemia.
[23] D. Esseltine,et al. Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] J. Reynolds,et al. Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] M. Boccadoro,et al. Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial. , 2008, Blood.
[26] B. Barlogie,et al. Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities. , 2008, Blood.
[27] Bin Jiang,et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. , 2008, The New England journal of medicine.
[28] Serge Leyvraz,et al. Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. , 2006, Blood.
[29] B. Barlogie,et al. International uniform response criteria for multiple myeloma , 2006, Leukemia.
[30] S. Jagannath,et al. CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION , 1998, British journal of haematology.
[31] Josef Korinek,et al. Proceedings of the American Society of Clinical Oncology , 1982 .